Nexgel Inc. released its financial results for the second quarter of 2025, highlighting a significant improvement in its financial performance. Net revenue for the quarter reached $2.88 million, doubling the $1.44 million reported in the same period of 2024, and slightly up from $2.81 million in the first quarter of 2025. The company also reported a gross profit of $1.26 million, compared to $0.29 million in the second quarter of 2024 and $1.19 million in the first quarter of 2025. The gross profit margin improved to 43.6%, up from 20.3% in the same quarter of the previous year. Nexgel's net loss attributable to stockholders for the second quarter of 2025 was $0.67 million, a reduction from the $0.89 million loss experienced in the second quarter of 2024, and slightly lower than the $0.71 million loss recorded in the first quarter of 2025. The company's EBITDA, a non-GAAP financial measure, was reported at ($0.53) million, improving from ($0.76) million in the second quarter of 2024 and ($0.58) million in the first quarter of 2025. Adjusted EBITDA also showed positive momentum, reported at ($0.42) million, compared to ($0.79) million in the same period of 2024 and ($0.50) million in the first quarter of 2025. Nexgel continues to expand its strategic partnerships, including contract manufacturing relationships with leading consumer healthcare companies. The company anticipates significant growth opportunities in the second half of 2025 driven by new consumer product launches and onboarding new contract manufacturing customers. Nexgel expects to generate at least $13 million in revenue for the entire year and aims to achieve positive EBITDA during 2025.